再鼎医药(09688.HK)获Mirati抑制产品独家授权
再鼎医药(09688.HK)公布,与Mirati Therapeutics, Inc.(MRTX.US),公司将有权在大中华区(中国内地、香港、澳门及台湾)研究、开发、制造及独家商业化小分子KRASG12C抑制剂adagrasib。
公司将向Mirati支付6,500万美元的预付款,Mirati可收支高达约2.73亿美元的潜在里程碑付款及高百分之十几至低百分之二十几的分级授权金。
再鼎医药将支持adagrasib在关键全球性支持注册的临床研究,以加速KRAS G12C突变癌症患者的入组,而Mirati可选择在大中华区共同商业化adagrasib ,并保留adagrasib在大中华区以外所有国家和地区的全面和独家权利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.